3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
pembrolizumab
20
Bevacizumab
14
Carboplatin
12
Standard of Care
10
Nivolumab
9
Cyclophosphamide
9
Cetuximab
8
Pemetrexed
7
Exercise
7
Doxorubicin
7
durvalumab
6
atezolizumab
6
Temozolomide
6
Radiotherapy
6
Prednisone
6
Paclitaxel
6
Cisplatin
6
Blood Specimen Collection
6
abemaciclib
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
olaparib
4
dostarlimab
4
Rituximab
4
Leucovorin
4
Gemcitabine
4
Fulvestrant
4
Docetaxel
4
Dexamethasone
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled